| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC35A4 |
| Uniprot No | Q96G79 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-324 aa |
| 活性数据 | MSVEDGGMPGLGRPRQARWTLMLLLSTAMYGAHAPLLALCHVDGRVPFRPSSAVLLTELTKLLLCAFSLLVGWQAWPQGPPPWRQAAPFALSALLYGANNNLVIYLQRYMDPSTYQVLSNLKIGSTAVLYCLCLRHRLSVRQGLALLLLMAAGACYAAGGLQVPGNTLPSPPPAAAASPMPLHITPLGLLLLILYCLISGLSSVYTELLMKRQRLPLALQNLFLYTFGVLLNLGLHAGGGSGPGLLEGFSGWAALVVLSQALNGLLMSAVMKHGSSITRLFVVSCSLVVNAVLSAVLLRLQLTAAFFLATLLIGLAMRLYYGSR |
| 分子量 | 61 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于人源SLC35A4蛋白的**假设性参考文献示例**，供参考(实际文献可能较少，建议通过数据库补充检索)：
1. **标题**: *"SLC35A4: A novel UDP-sugar transporter involved in Golgi glycosylation pathways"*
**作者**: Smith A, et al.
**摘要**: 本研究通过体外转运实验发现，SLC35A4蛋白可特异性转运UDP-葡萄糖和UDP-半乳糖至高尔基体腔，并通过CRISPR敲除细胞模型证实其参与N-连接糖基化修饰过程，为SLC35家族功能多样性提供证据。
2. **标题**: *"Genomic analysis links SLC35A4 to congenital disorders of glycosylation"*
**作者**: Zhang Y, et al.
**摘要**: 通过对罕见糖基化疾病患者的全外显子测序，发现SLC35A4基因存在功能缺失突变，细胞模型显示突变导致高尔基体糖转运活性下降，提示SLC35A4可能与先天性糖基化缺陷相关。
3. **标题**: *"Structural prediction and phylogenetic conservation of SLC35A4 transmembrane domains"*
**作者**: Tanaka K, et al.
**摘要**: 通过生物信息学分析预测SLC35A4的10次跨膜拓扑结构，并与SLC35家族其他成员(如SLC35A2)进行进化保守性对比，揭示了其底物结合位点的关键氨基酸残基。
4. **标题**: *"SLC35A4 expression is upregulated in hepatocellular carcinoma and promotes tumor progression"*
**作者**: Wang L, et al.
**摘要**: 研究发现SLC35A4在肝癌组织中高表达，通过调控细胞表面整合素糖基化影响肿瘤细胞迁移和侵袭，提示其可能作为癌症治疗的潜在靶点。
---
**注意**：以上为示例性内容，SLC35A4的研究尚有限，实际文献需通过 **PubMed/Google Scholar** 以关键词 "SLC35A4" 或 "human SLC35A4 protein" 检索。可结合 **UniProt(ID: Q96G79)** 或 **NCBI Gene(ID: 113149)** 获取基础信息。
Recombinant human SLC35A4 protein belongs to the solute carrier 35 (SLC35) family, a group of nucleotide sugar transporters located in the membranes of the Golgi apparatus and endoplasmic reticulum. SLC35A4 is implicated in the transport of cytidine monophosphate (CMP)-linked sialic acid, a critical substrate for protein sialylation, which influences cell-cell recognition, immune responses, and signal transduction. Although its exact mechanism remains less characterized compared to other SLC35 members, SLC35A4 is proposed to play a role in maintaining glycosylation homeostasis, a process vital for cellular communication and protein stability. Structurally, it is predicted to contain multiple transmembrane domains typical of transporter proteins.
Studies suggest SLC35A4 dysregulation may correlate with pathological conditions, including cancers, where altered glycosylation patterns are often observed. Its expression has been detected in various tissues, with elevated levels noted in certain tumors, hinting at potential diagnostic or therapeutic relevance. Recombinant SLC35A4 is engineered using heterologous expression systems (e.g., mammalian or insect cells) to study its biochemical properties, substrate specificity, and interactions. Despite progress, functional studies remain limited, necessitating further research to elucidate its physiological roles and disease associations. This protein represents a promising target for exploring glycosylation-related disorders and developing glycoengineering applications.
×
